Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 414-420

  Ajbani, Kanchan ^a   Lin, Shou Yean Grace ^b   Rodrigues, Camilla ^a   Nguyen, Duylinh ^b   Arroyo, Francine ^b   Kaping, Janice ^c   Jackson, Lynn ^c   Garfein, Richard S ^c   Catanzaro, Donald ^c   Eisenach, Kathleen ^d   Victor, Thomas C ^e   Crudu, Valeru ^f   Gler, Maria Tarcela ^g   Ismail, Nazir ^h   Desmond, Edward ^b   Catanzaro, Antonino ^c   Rodwell, Timothy C ^c  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF STELLENBOSCH   (South Africa)

^f Microbiology and Morphology Laboratory   (Moldova)

^g MAKATI MEDICAL CENTER   (Philippines)

^h National Reference Laboratory for Tuberculosis   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ISONIAZID; KANAMYCIN; KATG PROTEIN; MOXIFLOXACIN; NUCLEOTIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; SPACER DNA; TUBERCULOSTATIC AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; CATALASE; DNA DIRECTED RNA POLYMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); INHA PROTEIN, MYCOBACTERIUM; KATG PROTEIN, MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASE; RPOB PROTEIN, MYCOBACTERIUM TUBERCULOSIS;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE LOCUS; GENE TARGETING; GENOTYPE; INDIA; MOLDOVA; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PHILIPPINES; PROMOTER REGION; PYROSEQUENCING; SOUTH AFRICA; DNA SEQUENCE; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PROCEDURES;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BASE SEQUENCE; CATALASE; DNA GYRASE; DNA, BACTERIAL; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 84920198346     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03614-14     Document Type: Article

References (47)

1. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. 2012. Totally drugresistant tuberculosis in India. Clin Infect Dis 54:579-U156. http://dx.doi .org/10.1093/cid/cir889.
2. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136:420-425. http://dx.doi.org/10 .1378/chest.08-2427.
3. Klopper M, Warren RM, Hayes C, van Pitttius CG, Streicher EM, Müller B, Sirgel FA, Chabula-Nxiweni M, Hoosain E, Coetzee G, van Helden DP, Victor TC, Trollip AP. 2013. Emergence and spread of extensively and totally drug resistant tuberculosis, South Africa. Emerg Infect Dis 19:449-455. http://dx.doi.org/10.3201/eid1903.120246.
4. World Health Organization. 2011. Global tuberculosis control. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstr eam/10665/44728/1/9789241564380-eng.pdf?ua=1.
5. World Health Organization. 2013. Global tuberculosis report 2013. Report WHO/HTM/TB/2013.11. World Health Organization, Geneva, Switzerland.
6. World Health Organization. 2011. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2011/9789241501330-eng.pdf.
7. World Health Organization. 2008. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDRTB). World Health Organization, Geneva, Switzerland.
8. World Health Organization. 2010. Roadmap for rolling out Xpert MTB/ RIF for rapid diagnosis of TB and MDR-TB. World Health Organization, Geneva, Switzerland.
9. World Health Organization. 2013. The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. Report WHO/HTM/TB/2013.01. World Health Organization, Geneva, Switzerland.
10. Diggle MA, Clarke SC. 2004. Pyrosequencing: sequence typing at the speed of light. Mol Biotechnol 28:129-137. http://dx.doi.org/10.1385/M B:28:2:129.
11. Garcia-Sierra N, Lacoma A, Prat C, Haba L, Maldonado J, Ruiz-Manzano J, Gavin P, Samper S, Ausina V, Domínguez J. 2011. Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 49:3683-3686. http://dx.doi.org/10.1128/JCM.01239-11.
12. Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE. 2006. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by pyrosequencing technology. J Clin Microbiol 44:1925-1929. http: //dx.doi.org/10.1128/JCM.02210-05.
13. Marttila HJ, Makinen J, Marjamaki M, Soini H. 2009. Prospective evaluation of pyrosequencing for the rapid detection of isoniazid and rifampin resistance in clinical Mycobacterium tuberculosis isolates. Eur J Clin Microbiol Infect Dis 28:33-38. http://dx.doi.org/10.1007/s10096-008-0584-5.
14. Engstrom A, Morcillo N, Imperiale B, Hoffner SE, Jureen P. 2012. Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. J Clin Microbiol 50:2026-2033. http://dx.doi.org/10.1128/JCM.06664-11.
15. Lin G, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, Desmond EP. 2014. Pyrosequencing for rapid detection of extensively drug-resistant tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol 52:475-482. http://dx.doi.org/10.1128/JCM.01821-13.
16. Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, Van Deun A. 2013. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 51:2641-2645. http://dx.doi.org/10.112 8/JCM.02741-12.
17. Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC. 2013. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 51:2633-2640. http://dx.doi.org/10.1128/JCM.00553-13.
18. Rodwell TC, Valafar F, Douglas J, Douglas L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Kim MS, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gler MT, Catanzaro A. 2014. Predicting extensively drugresistant tuberculosis (XDR-TB) phenotypes with genetic mutations. J Clin Microbiol 52:781-789. http://dx.doi.org/10.1128/JCM.02701-13.
19. Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, Garfein RS, Lin S, Eisenach K, Ganiats TG, Park D, Valafar F, Rodrigues C, Crudu V, Victor TC, Catanzaro A. 2014. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials 15:434. http://dx.doi.org/10.1186/1745 -6215-15-434.
20. Siddiqi SH, Rüsch-Gerdes S. 2006. MGIT procedure manual for BACTEC MGIT 960 TB system. FIND Diagnostics, Geneva, Switzerland.
21. World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. ReportWHO/HTM/TB/ 2008.392. World Health Organization, Geneva, Switzerland.
22. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. 2008. Drug susceptibility testing of Mycobacterium tuberculosis against secondline drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis 12:1449-1455.
23. Das S, Paramasivan CN, Lowrie DB, Prabhakar Narayanan RR. 1995. IS6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, South India. Tuberc Lung Dis 76:550-554. http://dx .doi.org/10.1016/0962-8479(95)90533-2.
24. Kelley CL, Rouse DA, Morris SL. 1997. Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 41:2057-2058.
25. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE, III, Stover CK. 1996. Compensatory ahpC gene expression in isoniazidresistant Mycobacterium tuberculosis. Science 272:1641-1643. http://dx .doi.org/10.1126/science.272.5268.1641.
26. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. 2006. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31. http://dx.doi.org/10.1186/1471-2288-6-31.
27. Newcombe RG. 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17:857-872. http://dx .doi.org/10.1002/(SICI)1097-0258(19980430)17:8 - 857::AID -SIM7773.0.CO;2-E.
28. Vollset SE. 1993. Confidence intervals for a binomial proportion. Stat Med 12:809. http://dx.doi.org/10.1002/sim.4780120902.
29. Santos LC. 2012. Review: the molecular basis of resistance in Mycobacterium tuberculosis. Open J Med Microbiol 2:24-36. http://dx.doi.org/10 .4236/ojmm.2012.21004.
30. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. 2000. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 182:1788-1790. http://dx.doi.org/10.1086/317598.
31. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, Rigouts L, Rüsch-Gerdes S, Wright A. 2009. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 47:3501-3506. http://dx.doi.org/10.1128/JCM.01209-09.
32. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. 2014. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 69:331-342. http://dx.doi.org/10.1093/jac/dkt358.
33. Angeby K, Jureen P, Kahlmeter G, Hoffner SE, Schon T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90:693-698. http://dx .doi.org/10.2471/BLT.11.096644.
34. Yu Pang Jie Lu Yufeng Wang Yuanyuan Song Shengfen Wang and Yanlin Zhao. 2013. Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob. Agents Chemother 57:893-900. http://dx.doi.org/10.1128/AAC.01024-12.
35. th Gen Meet Am Soc Microbiol. American Society for Microbiology, Washington, DC.
36. Chen J, Chen Z, Li Y, Xia W, Chen X, Chen T, Zhou L, Xu B, Xu S. 2012. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz J Infect Dis 16:136-141. http://dx.doi.org/10.1016 /S1413-8670(12)70294-5.
37. Bottger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17:1128-1134. http://dx.doi .org/10.1111/j.1469-0691.2011.03551.x.
38. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 67:1088-1093. http://dx.doi.org/10.1093 /jac/dks033.
39. Jureen P, Angeby K, Sturegard E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T. 2010. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol 48:1853-1858. http://dx.doi.org/10.1128/JCM.00240-10.
40. Sirgel FA, Tait M, Warren RM, Streicher EM, Böttger EC, van Helden PD, Gey van Pittius NC, Coetzee G, Hoosain EY, Chabula-Nxiweni M, Hayes C, Victor TC, Trollip A. 2012. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist 18:193-197. http://dx.doi.org/10 .1089/mdr.2011.0063.
41. Via LE, Cho SN, Hwang S, Bang H, Park SK, Kang HS, Jeon D, Min SY, Oh T, Kim Y, Kim YM, Rajan V, Wong SY, Shamputa IC, Carroll M, Goldfeder L, Lee SA, Holland SM, Eum S, Lee H, Barry CE. 2010. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug resistant tuberculosis. J Clin Microbiol 48:402-411. http://dx.doi.org/10.1128/JCM.01476-09.
42. Sowajassatakul A, Prammananan T, Chaiprasert A, Phunpruch S. 2014. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand. BMC Microbiol 14: 165. http://dx.doi.org/10.1186/1471-2180-14-165.
43. Reeves AZ, Campbell PJ, Sultana R, Malik S, Murray M, Plikaytis BB, Shinnick TM, Posey JE. 2013. Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5= untranslated region of whiB7. Antimicrob. Agents Chemother 57:1857-1864. http://dx.doi.org /10.1128/AAC.02191-12.
44. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:e33275. http://dx.doi.org/10.1371 /journal.pone.0033275.
45. Guo HL, Seet Q, Denkin S, Parsons L, Zhang Y. 2006. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 55:1527-1531. http://dx.doi .org/10.1099/jmm.0.46718-0.
46. Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, Quitugua T, Graviss EA. 2003. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:1241-1250. http://dx.doi.org/10.1128/AAC .47.4.1241-1250.2003.
47. Zaunbrecher MA, Sikes RD, Jr, Metchock B, Shinnick TM, Posey JE. 2009. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 106:20004-20009. http://dx.doi.org /10.1073/pnas.0907925106.